Co-Diagnostics, Inc. Common Stock (CODX) — Cash Flow-to-Debt Ratio
Co-Diagnostics, Inc. Common Stock (CODX) has a Cash Flow-to-Debt Ratio of -1.51x as of December 2025, meaning its operating cash flow of $-6.20 Million could theoretically repay -2% of its total liabilities ($4.11 Million) in one year. See Co-Diagnostics, Inc. Common Stock free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Co-Diagnostics, Inc. Common Stock Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Co-Diagnostics, Inc. Common Stock across 12 annual periods. Also explore Co-Diagnostics, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Co-Diagnostics, Inc. Common Stock (2014–2025)
Year-by-year debt coverage analysis for Co-Diagnostics, Inc. Common Stock. For market capitalisation and broader financial context, see CODX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.08x | $-29.14 Million | $4.11 Million | ▼ -135.3% |
| 2024 | -3.01x | $-29.16 Million | $9.69 Million | ▼ -26.8% |
| 2023 | -2.37x | $-22.08 Million | $9.31 Million | ▼ -409.4% |
| 2022 | 0.77x | $6.57 Million | $8.57 Million | ▼ -52.3% |
| 2021 | 1.61x | $41.08 Million | $25.56 Million | ▼ -74.1% |
| 2020 | 6.20x | $28.17 Million | $4.54 Million | ▲ +153.7% |
| 2019 | -11.56x | $-5.53 Million | $478.07K | ▼ -639.9% |
| 2018 | -1.56x | $-4.08 Million | $2.61 Million | ▲ +60.5% |
| 2017 | -3.96x | $-3.21 Million | $811.80K | ▼ -1193.4% |
| 2016 | -0.31x | $-1.31 Million | $4.29 Million | ▲ +69.7% |
| 2015 | -1.01x | $-1.53 Million | $1.52 Million | ▲ +86.8% |
| 2014 | -7.63x | $-925.23K | $121.22K | — |